Literature DB >> 33489442

Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation.

Amit Bansal1, Preethi Jeyaraman2, S K Gupta1, Nitin Dayal3, Rahul Naithani2.   

Abstract

BACKGROUND: Infections are major contributor to morbidity and mortality in patients undergoing bone marrow transplant (BMT).
OBJECTIVE: To assess role of serum procalcitonin (PCT) as a useful biomarker for the infections and outcomes in these patients.
METHODS: Retrospective observational study.
RESULTS: Total 47 patients with febrile episodes were enrolled. Twenty patients underwent autologous BMT and 27 underwent allogeneic BMT. Bacterial infections were documented in 18/47 (38%) patients. Forty patients were neutropenic. The median fever duration was 10 days (range 3-30 days) in positive procalcitonin level group whereas it was 4 days (range 1-18) in negative group. This was statistically significant (P=0.000). Procalcitonin levels were high in 8/9 episodes of sepsis (P=0.029). Intensive care unit transfers and death were significantly higher in PCT positive group as compared to PCT negative group.
CONCLUSION: Serum procalcitonin levels provide prognostic information of worse outcome in patients undergoing HSCT. AJBR
Copyright © 2020.

Entities:  

Keywords:  Bone marrow transplant; infection; procalcitonin

Year:  2020        PMID: 33489442      PMCID: PMC7811896     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  21 in total

1.  Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors:  K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa
Journal:  Infection       Date:  2014-09-30       Impact factor: 3.553

2.  Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.

Authors:  Vipul Sheth; Fernanda Volt; Jaime Sanz; Laurence Clement; Jan Cornelissen; Didier Blaise; Jorge Sierra; Mauricette Michallet; Riccardo Saccardi; Vanderson Rocha; Eliane Gluckman; Christian Chabannon; Annalisa Ruggeri
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-26       Impact factor: 5.742

3.  Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma in India.

Authors:  Rahul Naithani; Nitin Dayal; Reeta Rai; Sangeeta Pathak; Manoj Singh
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-22       Impact factor: 0.900

4.  Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation.

Authors:  M Sato; H Nakasone; K Terasako-Saito; K Sakamoto; R Yamazaki; Y Tanaka; Y Akahoshi; H Nakano; T Ugai; H Wada; R Yamasaki; Y Ishihara; K Kawamura; M Ashizawa; S-i Kimura; M Kikuchi; A Tanihara; J Kanda; S Kako; J Nishida; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

5.  Diagnostic value of sepsis biomarkers in hematopoietic stem cell transplant recipients in a condition of high prevalence of gram-negative pathogens.

Authors:  Igor Stoma; Igor Karpov; Anatoly Uss; Oleg Rummo; Natalia Milanovich; Igor Iskrov
Journal:  Hematol Oncol Stem Cell Ther       Date:  2016-10-20

6.  Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes.

Authors:  Pedro Puerta-Alcalde; Celia Cardozo; Francesc Marco; Maria Suárez-Lledó; Estela Moreno; Laura Morata; Francesc Fernández-Avilés; Gonzalo Gutiérrez-Garcia; Mariana Chumbita; Laura Rosiñol; Jose Antonio Martínez; Carmen Martínez; Josep Mensa; Álvaro Urbano; Montserrat Rovira; Alex Soriano; Carolina Garcia-Vidal
Journal:  Bone Marrow Transplant       Date:  2019-09-30       Impact factor: 5.483

7.  Comparison of Different Doses of Granulocyte Colony-stimulating Factor in the Treatment of High-risk Febrile Neutropenia in Children With Cancer.

Authors:  Zahide Orhan Ok; Serhan Kupeli; Gulay Sezgin; Ibrahim Bayram
Journal:  J Pediatr Hematol Oncol       Date:  2020-11       Impact factor: 1.289

8.  Clinical Progress Note: Procalcitonin in the Identification of Invasive Bacterial Infections in Febrile Young Infants.

Authors:  Marie E Wang; Nivedita Srinivas; Russell J McCulloh
Journal:  J Hosp Med       Date:  2021-03       Impact factor: 2.960

Review 9.  Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy.

Authors:  Ashitha L Vijayan; Shilpa Ravindran; R Saikant; S Lakshmi; R Kartik; Manoj G
Journal:  J Intensive Care       Date:  2017-08-03

10.  Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma.

Authors:  Bettina M Knoll; Jibran Ahmed; Michael Karass; Amandeep Aujla; Patricia McHale; Patricia Kretschmer; Amitabha Mazumder; Karen Seiter; Tauseef Ahmed; Seah H Lim
Journal:  Am J Hematol       Date:  2018-12-31       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.